This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Center for Veterinary Biologics | |
|---|---|
| Name | Center for Veterinary Biologics |
| Formed | 1970s |
| Preceding1 | National Veterinary Services Laboratory |
| Jurisdiction | United States Department of Agriculture |
| Headquarters | Ames, Iowa |
| Parent agency | Animal and Plant Health Inspection Service |
Center for Veterinary Biologics
The Center for Veterinary Biologics (CVB) is a regulatory unit within the United States Department of Agriculture's Animal and Plant Health Inspection Service responsible for the evaluation, licensing, and oversight of veterinary biological products in the United States. It interacts with stakeholders including manufacturers, academic institutions, and international bodies such as the World Organisation for Animal Health and the Food and Agriculture Organization of the United Nations while operating in the context of federal statutes like the Virus-Serum-Toxin Act. CVB activities touch on animal health programs administered by the United States Department of Health and Human Services and veterinary research at centers including the National Institutes of Health and the United States Department of Agriculture Research Service.
CVB regulates veterinary biologics including vaccines, therapeutic antisera, diagnostic kits, and immunomodulators used in species ranging from Bos taurus cattle to Canis lupus familiaris dogs and Gallus gallus domesticus poultry. The center performs product review, lot release testing, potency assays, and post-licensing surveillance while coordinating with federal laboratories such as the National Veterinary Services Laboratory and academic partners like Iowa State University College of Veterinary Medicine. CVB's remit involves interaction with trade associations such as the American Veterinary Medical Association, commercial firms including Zoetis, Merck & Co., and Boehringer Ingelheim, and international regulators like the European Medicines Agency and the Canadian Food Inspection Agency.
CVB traces lineage to laboratory and regulatory functions performed by the Bureau of Animal Industry in the late 19th and early 20th centuries and evolved through reorganizations within the United States Department of Agriculture and APHIS in the 1970s. Historical milestones include implementation of the Virus-Serum-Toxin Act enforcement updates, modernization of licensure procedures following recommendations from panels convened by the National Research Council and engagement with outbreaks such as the 1947 foot-and-mouth disease outbreak and the 1999 West Nile virus emergence in the Western Hemisphere. CVB has adapted to technological shifts driven by innovators like Emil von Behring and institutions such as the Rockefeller Institute and responded to regulatory developments influenced by reports from the Government Accountability Office.
CVB operates under the authority of APHIS and reports through the USDA Secretary of Agriculture hierarchy. Its governance includes program offices overseeing Licensing, Compliance, Policy, and Science Services linked to laboratories like the National Veterinary Services Laboratory and regional offices interacting with state agencies such as the Iowa Department of Agriculture and Land Stewardship and professional groups like the American Association of Veterinary Immunologists. Advisory input has been sought from panels convened by the Food and Drug Administration's Center for Veterinary Medicine and external advisory committees tied to the National Academies of Sciences, Engineering, and Medicine.
Authorized by statutes including the Virus-Serum-Toxin Act and operating within executive frameworks such as Federal Register rulemaking, CVB issues licenses, establishes standard requirements, and maintains master file systems for biological product submissions. It sets potency and safety test standards consistent with compendia like the Code of Federal Regulations and engages with international standards from the World Organisation for Animal Health and the Organisation for Economic Co-operation and Development. CVB collaborates with enforcement entities such as the United States Department of Justice when addressing criminal violations and coordinates recall activities with agencies including the Centers for Disease Control and Prevention when zoonotic risk is implicated.
The CVB licensing pathway requires submission of manufacturing data, potency assays, safety studies, and labeling consistent with regulatory guidance from APHIS and input from subject matter experts from institutions such as Cornell University and Texas A&M University. Review involves bench and challenge studies, lot release testing at the National Veterinary Services Laboratory, and inspection of manufacturing sites following principles adopted from the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Interactions with industry stakeholders like Elanco and biotech firms are structured through pre-submission meetings and risk-based assessment frameworks informed by precedent decisions from agencies such as the European Medicines Agency.
Post-licensure, CVB conducts surveillance via adverse event reporting systems, serological monitoring, and targeted investigations in partnership with state veterinary diagnostic laboratories, the Association of American Veterinary Medical Colleges, and federal partners including CDC and NIH when human health overlap exists. Enforcement tools include injunctions, product seizures, license suspensions, and civil penalties enforced in coordination with the United States Department of Justice and administrative law procedures in the Federal Register. CVB has engaged in high-profile compliance actions involving manufacturers and distributors, often publicized through trade journals and industry groups.
CVB supports and conducts research on assay development, diagnostic validation, and novel vaccine technologies, collaborating with laboratories such as National Institutes of Health institutes, university veterinary colleges, and biotechnology companies using platforms pioneered by entities like Moderna and Pfizer in mRNA vaccine research. Collaborative programs include interagency initiatives with the Department of Homeland Security on agroterrorism resilience, cooperative research agreements with Iowa State University, and participation in international harmonization through the World Organisation for Animal Health.
CVB's regulation shapes animal health markets, influences export certification alongside the United States Trade Representative, and affects clinical practice guidelines promoted by the American Veterinary Medical Association. Controversies have included disputes over licensing timelines, debates about field trial design raised by academic groups, and tensions with manufacturers over intellectual property and labeling, echoing cases referenced in reports by the Government Accountability Office and litigation involving major pharmaceutical companies. Public discussions have also arisen regarding CVB responses to emerging threats like avian influenza and the balancing of trade interests with biosecurity priorities.